CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2015 results and recent business activities.
“Ironwood delivered strong performance in 2015, leveraging a platform of great scientific innovation to advance multiple blockbuster opportunities in areas such as IBS-C/CIC, vascular and fibrotic diseases and refractory GERD,” said Peter Hecht, chief executive officer of Ironwood.
